Skip to main content
Premium Trial:

Request an Annual Quote

Warnex to Restate Financial Statements

NEW YORK (GenomeWeb News) – Warnex said today that it would restate its financial statements for prior years due to a non-cash accounting error in its presentation of the debt component of its 2002 and 2004 convertible debentures.
 
The Laval, Quebec-based bioanalytical services and lab testing firm said that due to the accounting error the liability component of the debentures was understated by CDN$615,255 (US$627,691) as of Dec. 31, 2006, and its net loss was understated by $313,597, or $.01 per share, for 2006. The firm said it would restate the 2006 comparative numbers when it reports its year-end 2007 results.
 
For fiscal year 2006, Warnex reported revenues of $21.1 million and a net loss of $17.9 million, or $.34 per share.
 
Warnex also said that although it would not file amended interim financial statements for the year 2007, it would restate the comparative 2007 numbers when disclosing its 2008 interim financial results.
 
“Although regrettable, this specific and isolated situation, which does not impact the cash flow of the company, is being rapidly corrected and does not impact the future outlook of the company,” Mark Busgang, president and CEO of Warnex, said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.